Results 61 to 70 of about 43,229 (277)

Navigating adverse immunostimulation: A practical guide for clinical researchers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort   +3 more
wiley   +1 more source

Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy

open access: yesVirology Journal, 2010
Background Chronic HCV infection combined with occult hepatitis B infection has been associated with liver enzymes flare, advanced hepatic fibrosis and cirrhosis, poor response to standard interferon-α, and increased risk of HCC.
Mohamed Lamiaa A   +3 more
doaj   +1 more source

Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients [PDF]

open access: yes, 2018
Cytomegalovirus (CMV) infection represents one of the main cause mortality after Stem Cell Transplantation. Recently, a protective effect of the T allele of rs12979860 IL28B Single Nucleotide Polymorphisms (SNPs) against CMV infection in the allogenic ...
Angeletti, S   +13 more
core   +1 more source

Pegylated interferon α2b versus pegylated interferon α2a for chronic hepatitis C: The unreached goal of superiority [PDF]

open access: yesJournal of Hepatology, 2009
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, for the IDEAL Study Team. Background
openaire   +3 more sources

Harnessing nanomaterials to precisely regulate the immunosuppressive tumor microenvironment for enhanced immunotherapy

open access: yesBMEMat, EarlyView.
The immunosuppressive tumor microenvironment, characterized by hypoxia, redox imbalance, elevated interstitial fluid pressure, and acidity, was comprehensively elucidated. This review discussed the etiology and consequences of the characteristics of the immunosuppressive tumor microenvironment, and analyzed the recent advancements in nanomaterials for ...
Wen Zhang   +7 more
wiley   +1 more source

Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report

open access: yesSão Paulo Medical Journal, 2017
CONTEXT: Recurrent respiratory papillomatosis (RRP) is the most common laryngeal tumor. During childhood, it may present in extremely severe forms defined by the need for frequent surgical procedures to relieve respiratory distress and/or involvement of ...
Rebecca Maunsell   +1 more
doaj   +1 more source

Liver transplantation for viral hepatitis in 2015 [PDF]

open access: yes, 2016
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria   +8 more
core   +1 more source

Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment

open access: yesGut and Liver, 2007
Combination therapy with inteferon-alpha and ribavirin is an approved therapy for patients with chronic hepatitis C. However, even with the use of pegylated interferon, response rates are still poor in many difficult-to-treat groups, especially with ...
doaj   +1 more source

Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function

open access: yesLung India, 2016
Pulmonary toxicity related to the use of pegylated interferon alpha-2a during treatment of hepatitis C infections is rare; nonetheless, some cases with fatal outcomes have been reported.
Arturo Cortés-Telles
doaj   +1 more source

Issues in selecting HCV‐infected candidates for anti‐viral treatment [PDF]

open access: yes, 2012
Watch the interview with the authors Answer questions and earn CMEPeer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91215/1/18_ftp ...
Ge   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy